Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 1998

View Archived Issues

Somatogen: Q2 1998 highlights and clinical trial update

Phase III results reported for Prosorba

Prokinetic motilin agonists in development at Ohmeda

Novel class of muscarinic receptor agonists described by Pfizer

Lilly patents new voltage-sensitive calcium channel antagonists for CNS disorders

Diosmetin derivatives for vascular disorders prepared at ADIR

Novel chemokine identified and characterized at Millennium

Vitamin D analogues disclosed by Roche for hyperproliferative disorders

New antifungals reported by J&J subsidiary

Phase II results reported for memantine in neuropathic pain

Roche patents vitamin D analogues for osteoporosis

Oxytocin antagonist licensed by Tokyo Tanabe enters clinic

Tanabe's Tanatril receives E.U. approval

Schering-Plough to copromote Novo Nordisk's Prandin

Antiemetic to be copromoted in Japan by Novartis and Kyowa Hakko

Phase I/II trial results reported for Neovastat in lung cancer

Complete efficacy reported for Viratrol in recurrent herpes labialis

Another SMART antibody advances to clinical testing

Aquila receives milestone payment from SKB under Stimulon agreement

Proleukin cleared for marketing in U.S. for melanoma indication

Suramin submitted for FDA approval for cancer indication

Caspase inhibitor reduces ischemia/reperfusion injury, attenuates apoptosis in vivo

Roche acquisition of Corange on track

Pharmacia & Upjohn licenses rights to Spanish antimigraine drug

European approval recommended for Optison

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...